{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:35:10Z","timestamp":1790094910039,"version":"4.0.1"},"reference-count":38,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["18K07331"],"award-info":[{"award-number":["18K07331"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["23K07869"],"award-info":[{"award-number":["23K07869"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Friends of Leukemia Research Fund","award":["18K07331"],"award-info":[{"award-number":["18K07331"]}]},{"name":"Friends of Leukemia Research Fund","award":["23K07869"],"award-info":[{"award-number":["23K07869"]}]},{"name":"Keio Gijuku Academic Development Fund","award":["18K07331"],"award-info":[{"award-number":["18K07331"]}]},{"name":"Keio Gijuku Academic Development Fund","award":["23K07869"],"award-info":[{"award-number":["23K07869"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Several anti-cancer drugs are known to have immunomodulatory effects, including immunogenic cell death (ICD) of cancer cells. ICD is a form of apoptosis which is caused by the release of damage-associated molecular patterns (DAMPs), the uptake of cancer antigens by dendritic cells, and the activation of acquired immunity against cancer cells. ICD was originally reported in solid tumors, and there have been few reports on ICD in multiple myeloma (MM). Here, we showed that proteasome inhibitors, including carfilzomib, induce ICD in myeloma cells via an unfolded protein response pathway distinct from that in solid tumors. Additionally, we demonstrated the potential impact of ICD on the survival of patients with myeloma. ICD induced by proteasome inhibitors is expected to improve the prognosis of MM patients not only by its cytotoxic effects, but also by building strong immune memory response against MM cells in combination with other therapies, such as chimeric antigen receptor\u2014T cell therapy.<\/jats:p>","DOI":"10.3390\/ph16101367","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T07:38:46Z","timestamp":1695800326000},"page":"1367","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4953-4834","authenticated-orcid":false,"given":"Maiko","family":"Matsushita","sequence":"first","affiliation":[{"name":"Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Kashiwazaki","sequence":"additional","affiliation":[{"name":"Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kamiko","sequence":"additional","affiliation":[{"name":"Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Kobori","sequence":"additional","affiliation":[{"name":"Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Osada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2318-2551","authenticated-orcid":false,"given":"Hisako","family":"Kunieda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7148-9278","authenticated-orcid":false,"given":"Maki","family":"Hirao","sequence":"additional","affiliation":[{"name":"Department of Health Science, Faculty of Sports and Health Science, Daito Bunka University, Saitama 355-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiju","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-9738","authenticated-orcid":false,"given":"Yutaka","family":"Hattori","sequence":"additional","affiliation":[{"name":"Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, Tokyo 105-8512, Japan"},{"name":"Department of Hematology, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.16674","article-title":"Incidence and survival of multiple myeloma: A population-based study of 10 524 patients diagnosed 1982\u20132017","volume":"191","author":"Langseth","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"684561","DOI":"10.3389\/fonc.2021.684561","article-title":"Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma","volume":"11","author":"Romano","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pinto, V., Bergantim, R., Caires, H.R., Seca, H., Guimar\u00e3es, J.E., and Vasconcelos, M.H. (2020). Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers, 12.","DOI":"10.3390\/cancers12020407"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2005.08.032","article-title":"Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte","volume":"123","author":"Gardai","year":"2005","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1158\/1078-0432.CCR-11-2701","article-title":"Molecular pathways: Involvement of immune pathways in the therapeutic response and outcome in breast cancer","volume":"19","author":"Andre","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41467-019-09415-3","article-title":"Crizotinib-induced immunogenic cell death in non-small cell lung cancer","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41419-019-2042-y","article-title":"EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells","volume":"10","author":"Sagar","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2016.08.019","article-title":"Inhibition of autophagy with chloroquine potentiates carfilzomib-induced apoptosis in myeloma cells in vitro and in vivo","volume":"382","author":"Jarauta","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Serrano-Del Valle, A., Anel, A., Naval, J., and Marzo, I. (2019). Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Front. Cell Dev. Biol., 7.","DOI":"10.3389\/fcell.2019.00050"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/s41418-017-0044-9","article-title":"eIF2\u03b1 phosphorylation is pathognomonic for immunogenic cell death","volume":"25","author":"Bezu","year":"2018","journal-title":"Cell Death Differ."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41419-021-03605-y","article-title":"Oleandrin, a cardiac glycoside, induces immunogenic cell death via the PERK\/elF2\u03b1\/ATF4\/CHOP pathway in breast cancer","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1776570","DOI":"10.1080\/23723556.2020.1776570","article-title":"EIF2\u03b1 phosphorylation: A hallmark of both autophagy and immunogenic cell death","volume":"7","author":"Humeau","year":"2020","journal-title":"Mol. Cell Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.7150\/jca.29421","article-title":"Unravel the molecular mechanism of XBP1 in regulating the biology of cancer cells","volume":"10","author":"Shi","year":"2019","journal-title":"J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Solari, J.I.G., Filippi-Chiela, E., Pilar, E.S., Nunes, V., Gonzalez, E.A., Figueir\u00f3, F., Andrade, C.F., and Klamt, F. (2020). Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06964-5"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: Structure and function","volume":"44","author":"Nunes","year":"2017","journal-title":"Semin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12185-016-2016-0","article-title":"Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma","volume":"104","author":"Ri","year":"2016","journal-title":"Int. J. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/emboj.2009.1","article-title":"Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death","volume":"28","author":"Panaretakis","year":"2009","journal-title":"EMBO J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.leukres.2016.07.006","article-title":"IRE1\u03b1-XBP1 signaling pathway, a potential therapeutic target in multiple myeloma","volume":"49","author":"Chen","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Schmitz, M.L., Shaban, M.S., Albert, B.V., G\u00f6k\u00e7en, A., and Kracht, M. (2018). The Crosstalk of Endoplasmic Reticulum (ER) Stress Pathways with NF-\u03baB: Complex Mechanisms Relevant for Cancer, Inflammation and Infection. Biomedicines, 6.","DOI":"10.3390\/biomedicines6020058"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6882","DOI":"10.1002\/jcb.26885","article-title":"Disulfiram\/copper targets stem cell-like ALDH+ population of multiple myeloma by inhibition of ALDH1A1 and Hedgehog pathway","volume":"119","author":"Jin","year":"2018","journal-title":"J. Cell Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3390\/curroncol28030193","article-title":"Possible Therapeutic Potential of Disulfiram for Multiple Myeloma","volume":"28","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"33444","DOI":"10.1038\/srep33444","article-title":"Copper(II) ions affect the gating dynamics of the 20S proteasome: A molecular and in cell study","volume":"6","author":"Santoro","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/gerona\/glu129","article-title":"ER Stress Response in Human Cellular Models of Senescence","volume":"70","author":"Matos","year":"2015","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"30625","DOI":"10.1074\/jbc.M114.571984","article-title":"Unspliced X-box-binding protein 1 (XBP1) protects endothelial cells from oxidative stress through interaction with histone deacetylase 3","volume":"289","author":"Martin","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1038\/bcj.2013.13","article-title":"A myelomacell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor","volume":"3","author":"Hattori","year":"2013","journal-title":"Blood Cancer J."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/10\/1367\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:59:42Z","timestamp":1760129982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/10\/1367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["ph16101367"],"URL":"https:\/\/doi.org\/10.3390\/ph16101367","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}